$0.43
+0.04 (+10.93%)
Open$0.39
Previous Close$0.39
Day High$0.44
Day Low$0.39
52W High$1.50
52W Low$0.38
Volume—
Avg Volume3.69M
Market Cap4.70M
P/E Ratio—
EPS$-1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,907.0% upside
Current
$0.43
$0.43
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.85M | 6.01M | 3.80M |
| Net Income | -13,019,538 | -8,976,240 | 985.2K |
| Profit Margin | -800.8% | -760.7% | 25.9% |
| EBITDA | -19,821,692 | -14,425,162 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +30.5% | +30.5% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |